Skip to main content
. 2024 Nov 8;14(12):3273–3290. doi: 10.1007/s13555-024-01292-z

Fig. 2.

Fig. 2

Achievements of efficacy endpoints over time: a sPGA, b DLQI 0/1, c PSS 0. CI confidence interval; DLQI Dermatology Life Quality Index; sPGA static Physicians Global Assessment; PSS Psoriasis Symptoms Scale. Non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 was used; CIs for response rate were based on the Wilson score method